Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272922 | 1.00 | SIGMAR1 (0.54) | SIGMAR1LTA4HCYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL3272931 | 1.00 | SIGMAR1 (0.54) | SIGMAR1LTA4HCYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL3276041 | 0.91 | SIGMAR1 (0.53) | SIGMAR1LTA4HALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3274127 | 0.91 | SIGMAR1 (0.53) | SIGMAR1LTA4HALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3274123 | 0.91 | SIGMAR1 (0.53) | SIGMAR1LTA4HALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL3278083 | 0.90 | SIGMAR1 (0.51) | SIGMAR1LTA4HALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4472074 | 0.90 | BCHE (0.49) | SIGMAR1LTA4HALDH1A1ACHEBCHE | |
| Hydrochloric Acid SCHEMBL3278090 | 0.90 | SIGMAR1 (0.51) | SIGMAR1LTA4HALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31235612 | 0.90 | ACHE (0.49) | SIGMAR1LTA4HACHEBCHEBACE1 | |
| SCHEMBL24835751 | 0.89 | LTA4H (0.48) | SIGMAR1LTA4HCYP2C19ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273883-B2 | Method for producing optically active 2-arylpiperazine derivative | KANEKA CORPORATION (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100087643-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | KANEKA CORPORATION (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2119709-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | Kaneka Corporation (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087643-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | CYP2W1, AGPS, DHPS | SIGMAR1 1692/4885LTA4H 1220/4885CYP2C19 204/4885 |
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | SIGMAR1 993/4885LTA4H 242/4885CYP2C19 802/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | SIGMAR1 256/4885LTA4H 1096/4885CYP2C19 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.